SynthesisInternational journal of clinical oncology2025
Different outcomes by sex in metastatic gastrointestinal stromal tumor patients receiving imatinib: a trial-level analysis.
Synthesis in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmong gastrointestinal stromal tumors patients, many authors have reported longer overall survival for female sex regardless of stage. Other studies showed more favourable prognosis for young women, while others found no effect of sex on outcome. Few data about survival differences by sex are available on patients with unresectable/metastatic gastrointestinal stromal tumors (mGIST) receiving imatinib. The study aims to perform a trial-level analysis of metastatic gastrointestinal stromal tumors patients treated with imatinib to define the effect of sex on overall survival.
methodsAfter a systematic literature review, studies enrolling mGIST patients receiving upfront imatinib and reporting hazard ratios and confidence intervals of the relationship of sex with overall survival (OS) were selected. A meta-analysis was performed, calculating a global effect size. Finally, the study explored the effect on the relationship of other baseline variables, such as age, sex, tumor location, and patient origin.
resultsFifteen articles were selected, including 3612 patients. The meta-analysis documented longer OS among women, with significant overall effect size (HR 0.77, CI 0.71-0.84). Furthermore, there was no significant heterogeneity among studies (Q=9.13, p-value=0.8229; I
conclusionsThe analysis documented better prognosis for female sex after upfront imatinib. The absence of heterogeneity between studies suggests that sex may condition a different response to imatinib. However, other factors, such as second malignancies and mutation patterns, may also contribute to the observed differences.
Indexed as
Identifiers
40488811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.